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Disposition and effect of intra-articularly 
administered dexamethasone 
on lipopolysaccharide induced equine synovitis
Carl Ekstrand1* , Ulf Bondesson2,3, Ellen Giving4, Mikael Hedeland2,3, Carina Ingvast‑Larsson1, Stine Jacobsen5, 
Maria Löfgren1, Lars Moen4, Marie Rhodin6, Tonje Saetra7 and Birgit Ranheim8
Abstract 
Background: Dexamethasone is used for the intra‑articular route of administration in management of aseptic 
arthritis in horses. Despite its widespread use there is very little quantitative data of the disposition and response to 
dexamethasone. The aim of this study was to investigate and describe the synovial fluid and plasma dexamethasone 
concentration over time and to explore the relation between synovial fluid concentration and response using clinical 
endpoints as response biomarkers after IA injection of dexamethasone disodium salt solution in an equine model of 
synovitis.
Results: Inflammation was induced in the radiocarpal joint of six horses by injection of 2 ng lipopolysaccharide (LPS). 
Two hours later either saline or dexamethasone was injected in the same joint in a two treatment cross over design. 
Each horse was treated once with one of the six doses dexamethasone used (0.01, 0.03, 0.1, 0.3, 1 or 3 mg) and once 
with saline. Dexamethasone was quantified by means of UHPLC–MS/MS. Dexamethasone disposition was character‑
ised by means of a non‑linear mixed effects model. Lameness was evaluated both objectively with an inertial sensor 
based system and subjectively scored using a numerical scale (0–5). Joint circumference, skin temperature over the 
joint and rectal temperature were also recorded. The LPS‑challenge induced lameness in all horses with high inter‑
individual variability. Dexamethasone significantly decreased lameness compared with saline. Other variables were 
not statistically significant different between treatments. Objective lameness scoring was the most sensitive method 
used in this study to evaluate the lameness response. A pharmacokinetic/pharmacodynamic model was successfully 
fitted to experimental dexamethasone and lameness data. The model allowed characterization of the dexamethasone 
synovial fluid concentration–time course, the systemic exposure to dexamethasone after intra‑articular administration 
and the concentration–response relation in an experimental model of synovitis.
Conclusions: The quantitative data improve the understanding of the pharmacology of dexamethasone and might 
serve as input for future experiments and possibly contribute to maintain integrity of equine sports.
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Background
Joint injury or disease is common in both equine ath-
letes and companion horses. In racehorses, the overall 
injury rate was estimated to 1.8 injuries per 100 months 
the horses were at risk for injuries, i.e. from entering the 
study until diagnosed with an injury [1]. Also, one-third 
of euthanised 2- to 3-year-old thoroughbred racehorses 
were diagnosed post mortem with metacarpophalangeal 
joint arthritis [2]. Intra-articular (IA) injections of gluco-
corticoids are routinely used in the treatment of equine 
joint disease. Both clinical studies and experimental stud-
ies demonstrate the effectiveness of glucocorticoids in 
the inflamed joint [3–7]. The effect of dexamethasone 
administered both intravenously (IV) and IA has been 
investigated after lipopolysaccharide (LPS) challenge of 
the equine joint using total protein concentration in syn-
ovial fluid as response biomarker [5]. However, that study 
only compared the effect after IV and IA administra-
tion and did not report any dexamethasone plasma nor 
synovial fluid concentrations of dexamethasone. Syno-
vial fluid concentrations and plasma disposition has been 
described for several glucocorticoids after IA administra-
tion to healthy joints [8–17]. This quantitative informa-
tion might also be used in anti-doping and medication 
control to assess irrelevant drug concentrations, which 
protect both animal welfare and the integrity of racing 
and equestrian sports [18, 19]. However, the disposi-
tion of dexamethasone in synovial fluid from inflamed 
joint has not been reported. The aim of this study was 
to investigate and describe the synovial fluid and plasma 
dexamethasone concentration over time and to explore 
the relation between synovial fluid concentration and 
response using clinical endpoints as response biomarkers 
after IA injection of dexamethasone disodium salt solu-
tion in an equine model of synovitis.
Methods
Animals
Three Standardbred mares and three Standardbred geld-
ings  (horses A–F), 3–9  years old and weighing 429–
550  kg, were included in the study. Immediately before 
collection of baseline data no signs of radiocarpal joint 
inflammation (joint effusion, heat) was detected upon 
clinical examination and front leg lameness was 1.5 or 
less (American Association of Equine Practitioners lame-
ness scale) during baseline collection.
Experimental design and intra‑articular injections
This study was prospective, randomised, placebo-con-
trolled and blinded. Three days before treatment, the 
horses were transported to the study location for accli-
matisation. The horses were assigned to an experi-
ment including two treatments, LPS + dexamethasone 
21-phosphate disodium salt solution (DSP, Dexadreson, 
2 mg/mL, Intervet AB, Sollentuna, Sweden) and for con-
trol LPS + saline was administered in the contralateral 
joint. Dexamethasone dose and treatment regimen is 
shown in Table 1.
During experimental periods, the horses were kept in 
individual boxes and fed hay and concentrate (Cham-
pion komplett, Felleskjøpet, Lillestrøm, Norway). Water 
was available ad  libitum. During wash-out periods the 
horses were on pasture. Before treatment, the hair over 
the jugular vein was clipped and the skin was disin-
fected with chlorhexidine solution and 70% ethanol. One 
2.1 × 130 mm intravenous catheter (MILA International 
Inc., Florence, KY, USA) was placed in the jugular vein 
and secured with three sutures. Before arthrocentesis, 
the hair over the radiocarpal joint was clipped and the 
skin was disinfected with chlorhexidine solution and 70% 
ethanol.
Inflammation was induced in the radiocarpal joint by 
means of LPS from Escherichia coli 055:B5 purified by 
phenol extraction (Product Number L2880) (Sigma-
Aldrich). A stock solution was prepared by diluting the 
LPS in sterile water. In a second step, the LPS was diluted 
in sterile physiological saline to a concentration of 1 ng/
mL. Aliquots were frozen at − 70 °C in siliconised tubes, 
thawed and vortexed for 15 min immediately before use, 
according to the manufacturer’s instructions. A total vol-
ume of 2 mL LPS solution was injected into the joint at 
time 0 using a glass syringe (Hamilton Company, Timis, 
Table 1 Dose and treatment regimen
LF left front, RF right front
Horse Dose (mg) Treatment #1 Limb Treatment #2 Limb
A 0.3 LPS + dexamethasone RF LPS + saline LF
B 0.1 LPS + saline LF LPS + dexamethasone RF
C 0.03 LPS + saline RF LPS + dexamethasone LF
D 1 LPS + saline LF LPS + dexamethasone RF
E 3 LPS + saline RF LPS + dexamethasone LF
F 0.01 LPS + dexamethasone LF LPS + saline RF
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Romania). Two hours after LPS injection, equivalent 
volumes (2  mL) of either 0.9% saline or DSP diluted in 
saline were injected into the joint. All joint injections 
and samplings were performed using 0.8 × 35  mm nee-
dles. Each of the six horses was treated with one dose 
dexamethasone injected once into the radiocarpal joint 
during LPS + DSP treatment. A minimum of 3  weeks 
wash-out period was applied between treatments. A 
nose twitch was applied before injections and collection 
of synovial fluid in order to restrict the horse from sud-
den movements. The study was approved by the Nor-
wegian Animal Research Authority (Forsøksdyrutvalget 
2013/61618-1).
Sampling protocol
Synovial fluid samples and plasma samples for drug 
concentration determination were collected at time − 2 
(before LPS injection) and 0 (before DSP or saline injec-
tion), 2, 4, 8, 22, 26, 30, 46, 50, 54, 70 and 74 h after DSP 
and saline injection. Three additional blood samples 
were also drawn at 5, 20 and 40 min after DSP and saline 
injection. Immediately before injection or sampling the 
skin over the joint was desensitised by means of a cool-
ing spray (Articare Cold Spray, BSN Medical Ltd. Hull, 
UK). Blood and synovia were centrifuged at 1800g for 10 
and 5 min, respectively. The supernatant was transferred 
to microcentrifuge tubes and immediately frozen at 
− 20 °C, moved within 24 h and stored at − 70 °C pend-
ing analysis.
Clinical endpoints (CEs) baseline was recorded three 
times, typically between 15.00 and 18.00 the day before 
LPS challenge. CEs were also recorded before collec-
tion of synovial fluid and at one additional occasion 6 h 
after dexamethasone administration. The CEs were: 
rectal temperature (RT) measured by means of a digital 
thermometer, local skin temperature (ST) measured by 
means of a digital infrared thermometer (Fluke 574 cf, SR 
Automation AS, Asker, Norway) and joint-circumference 
(JC) measured by means of a measuring-tape. Lame-
ness was evaluated in trot (8 × 20 m in a straight line on 
flat concrete floor indoors). Lameness was subjectively 
scored by three experienced clinicians using the Ameri-
can Association of Equine Practitioners (AAEP) lame-
ness scale. Objective lameness analysis was performed 
by means of a commercial inertial measure unit based 
gait analysis system (Lameness  Locator®, Equinosis, 
St. Louis, MO, USA) for lameness detection [20]. Two 
uni-axial accelerometer was used. One was mounted to 
a head bumper attached to the bridle over the poll and 
one was taped to the midline of the pelvis at the level of 
the tubera sacrale. One uni-axial gyroscope was attached 
dorsally to the proximal and middle phalanges of the 
right forelimb for stride segmentation. Vertical uni-axial 
acceleration was recorded at 200 Hz and data were trans-
mitted wirelessly from the sensors to a computer running 
the data collection software. Objective motion data were 
processed with the software package for the gait analysis 
system. Raw uni-axial acceleration signals from head and 
pelvis sensors, aligned with the global vertical axis in the 
standing position, were first transformed into displace-
ment signals using a custom-designed, error-correcting, 
double-integration technique and the signal from the 
right forelimb gyroscope [20]. From the displacement 
signal local minima of the head were identified (two 
per stride). Forelimb impact lameness was measured 
by means of differences between the two local minima 
 (HDmin) during left and right stance phases, computed 
for each stride. Results are reported as change in absolute 
 HDmin values from baseline.
Dexamethasone IV‑data
Dexamethasone plasma concentration–time data from 
a previous study [21] was used in the pharmacokinetic 
analyses in order to increase the data-set. In that study 
six Standardbred horses (four mares and two geldings) 
6–20 years old and weighing 430–584 kg were used in a 
randomized crossover design including three treatments 
with dexamethasone at various doses. Each treatment 
started with an intravenous bolus dose immediately fol-
lowed by 3  h of constant rate infusion of dexametha-
sone 21-phosphate disodium salt (Dexadreson 2  mg/
mL, Intervet AB, Sollentuna, Sweden). The dose levels 
were (bolus + infusion) 0.1 + 0.07  μg/kg, 1 + 0.7  μg/kg 
and 10 + 7 μg/kg dexamethasone. Before the bolus dose 
(time = 0) a pre-dose blood sample was drawn. Addi-
tional blood samples were drawn during and after infu-
sion at hours 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36 and 48. A 
minimum of a 1-week wash-out period was allowed 
between drug treatments.
Dexamethasone quantification
Plasma and synovial fluid dexamethasone concentrations 
were analysed and quantified with the use of ultra high 
performance liquid chromatography–tandem mass spec-
trometry (UHPLC–MS/MS). Dexamethasone reference 
compound was acquired from Toronto Research Chemi-
cals (North York, ON, Canada) and the internal standard 
2H4-dexamethasone (dexamethasone-d4) was purchased 
from CDN Isotopes through QMX Laboratories Ltd. 
(Essex, UK). The water was purified using a Milli-Q water 
purification system (Millipore, Bedford, MA, USA). All 
other chemicals were of analytical grade or better and 
used without further purification. Synovial fluid from 
control treatment was used as blank matrix for prepara-
tions of calibrators and control samples (QC).
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Samples were pretreated by diluting each synovial 
sample (50 µL) with 950 µL of aqueous potassium phos-
phate buffer (0.1  M, pH 6.05). To 100  µL of the diluted 
sample, 50 µL of the internal standard (dexamethasone-
d4, 0.05  µg/mL), 500  µL of potassium phosphate buffer 
(0.1  M, pH 6.05) were added. Liquid–liquid extraction 
was carried out to 2.0 mL tert-butylmethylether by vor-
tex mixing for 5  min and subsequent centrifugation for 
10 min. To facilitate phase separation, the samples were 
then frozen at − 70 °C for 30 min after which the organic 
phase was decanted to another tube and evaporated 
under a gentle stream of air at 55  °C. The samples were 
reconstituted in 100  µL of aqueous formic acid (0.1%)/
methanol (1:1 v/v) and transferred to vials for UHPLC–
MS/MS analysis.
The extracts were analyzed with UHPLC–MS/MS. A 
Waters Acquity UPLC system was coupled to a Quat-
tro Ultima Pt tandem quadrupole mass spectrometer 
with an electrospray interface operating in the positive 
mode (Waters Corporation, Milford, MA). The column 
was an Acquity UPLC BEH C18 (length 100  mm, I.D. 
2.1  mm, particle size 1.7  µm) from Waters Corporation 
kept at 65 °C. The mobile phase consisted of (A) ammo-
nium acetate (aq, 2.0 mM) and (B) formic acid (0.1%) in 
acetonitrile. A gradient was run as follows: initially 23% 
B for 4.7  min, 23–90% B in 0.1  min, constant at 90% B 
for 1.0 min, 90–23% B in 0.1 min, constant at 23% B for 
0.9 min. The total run time was 6.8 min, the flow rate was 
650 µL/min and the injection volume was 10 µL.
The mass spectrometric settings were as follows: a posi-
tive capillary voltage of 3.5 kV, the desolvation and source 
block temperatures were 300 °C and 120 °C and the cone 
and desolvation gas flows were 121 and 830 L/h, respec-
tively. The quantifications were performed in the selected 
reaction monitoring (SRM) mode with the collision cell 
filled with argon gas at a pressure of 2.4 × 10−3 mBar. The 
transitions used in SRM were m/z 393 → 355 for dexa-
methasone (collision energy 14 eV, cone voltage 50 V) and 
m/z 397 → 359 for dexamethasone-d4 (collision energy 
14 eV, cone voltage 50 V). The dwell time was 0.01 s.
Stock solutions of dexamethasone, and the internal 
standard were prepared in methanol at approximately 
0.3  mg/mL. These solutions were diluted and used to 
spike blank synovial fluid to obtain calibration and QC 
samples. The calibration was performed by linear curve 
fit (weighting factor of 1/x2) of the peak area ratio (ana-
lyte/internal standard) as a function of the analyte con-
centration. The LLOQ for dexamethasone in synovial 
fluid was 0.38  ng/mL. The precision expressed as the 
relative standard deviation (RSD) in the results of quality 
control samples in synovia was in the interval 2.7–7.8% 
and the accuracy was in the range of 97–109%.
The analytical method for dexamethasone in plasma is 
further described in our previous work [22]. The lower 
limit of quantification (LLOQ) for dexamethasone in 
plasma was 0.025 ng/mL.
Dexamethasone concentration–time analyses
A non-linear mixed effects (NLME) approach that is 
the appropriate tool [23] to analyse unbalanced data set 
obtained in different trials was used to estimate pharma-
cokinetic and pharmacodynamic parameters. A compre-
hensive three compartment model (Fig.  1) was fitted to 
the dexamethasone synovial fluid concentration–time 
data from the six horses in the current study and to the 
dexamethasone plasma concentration–time data in the 
current study and from the study in [21]. The disposition 
of dexamethasone in synovial fluid was described as:
where Amtsyn and Amtp are the dexamethasone amount 
in synovial fluid and in plasma, respectively. The kpa, kap 
and kel are the first-order rate constants from plasma to 
synovial fluid, from synovial fluid to plasma and for direct 
elimination from the joint, respectively. The dexametha-
sone synovial fluid concentration (Csyn) was obtained by:
For identifiability reason, the average volume of the syn-
ovial compartment (Vsyn) was fixed at 0.2 mL/kg and the 
individual value for each horse (Vhorse) was obtained by:
where ηhorse is the deviation of each horse from its (fixed) 
typical value.
The disposition of dexamethasone in the central com-
partment after IA administration of dexamethasone was 
described as:
where Cp and Ct denote the dexamethasone concentra-
tion in synovial fluid, the central and peripheral com-
partment, respectively. Amtsyn, kpa and kap as defined in 
Eq. (1), Cl is the plasma clearance of dexamethasone and 
Cld is the inter-compartmental distribution. Dexametha-
sone disposition in the central compartment after IV 
administration of dexamethasone was described as:
(1)
dAmtsyn
dt
=
[
Amtp · kpa − Amtsyn · kap]−[Amtsyn · kel
]
(2)Csyn =
Amtsyn
Vsyn
(3)Vhorse = 0.2 · eηhorse
(4)
dAmtp
dt
= −
[
Cl · Cp
]
− Cld ·
[
Cp − Ct
]
−
[
Amtp · kpa − Amtsyn · kap
]
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and the dexamethasone amount in the peripheral com-
partment Amtt was described as:
where Cp and Ct were obtained by Eqs. (7) and (8):
(5)dAmtp
dt
= −
[
Cl · Cp
]
− Cld ·
[
Cp − Ct
]
(6)Amtt = Cld ·
(
Cp − Ct
)
(7)Cp =
Amtp
Vc
(8)Ct =
Amtt
Vt
Vsyn
RLL
kap Cld
LPS·I(Csyn) kout·R
a
b
Vc
Dose
Dose
Vsyn
kap
kpa
Kel
Vc
Vt
Cld
Cl
LPS 
I(Csyn)
RLL
kout
kpa
Vt
kel
Cl
= the dose dexamethasone administered intra-articularly
= the volume of distribution in the synovial compartment (fixed to 0.2 mL/kg)
= the rate constant for distribution from synovial fluid to plasma
= the rate constant for distribution from plasma to synovial fluid
= the rate constant for direct elimination of dexamethasone from the joint
= the central volume of distribution
= the peripheral volume of distribution
= the inter-compartmental distribution parameter between the central and the
peripheral compartment
= clearance of dexamethasone from plasma
= LPS-challenge function
= inhibitory drug mechanism function
= Lameness response
= first-order fractional turnover rate of the response
Dose
Fig. 1 Illustration of the sequential approach that was adopted to estimate the PK/PD parameters. The upper row shows the dexamethasone 
synovial fluid and plasma disposition model (a) and the lower row the pharmacodynamic model (b) describing the LPS challenge and lameness 
response (RLL). The post hoc estimates of individual PK parameters were fixed to their post hoc estimate to “drive” the drug‑mechanism function 
(I(Csyn)) acting on production of lameness response induced by the LPS‑challenge [25]
Page 6 of 17Ekstrand et al. Acta Vet Scand           (2019) 61:28 
where Vc is the central volume of distribution, Vt is the 
peripheral volume of distribution.
The between subject variability (BSV) was described 
using an exponential model of the form:
where θparameter_i is the value of theta for respective 
parameter in the ith horse, θtv_parameter is the typical pop-
ulation value of the parameter (e.g. Vc, Vt, Cl, Cld etc.) 
and ηi is the deviation from the corresponding theta pop-
ulation value associated to the ith horse. The exponential 
model assumes a log-normal distribution of parameters, 
i.e. that the distribution of the etas ( ηi ) is normal in the 
log-domain, with a mean of 0 and a variance ω2 where:
Shrinkage of random effects toward the means accord-
ing to Karlsson and Savic [24] was described as:
where SD(EBEη) is the standard deviation of the individ-
ual values of the Empirical Bayesian Estimates (EBE) of η.
When the three compartment model was fitted to IV-
data from the study in [21], clearance was assumed to 
possibly vary with dose and was considered as a covariate 
described as:
where θtv, θ1 and doselevel are the typical value for clear-
ance for a theoretical dose of 0, θ1 reflect the change in 
clearance by dose level and the dose level, respectively.
From the model parameters following secondary 
parameters were derived:
The terminal slope (βp) of the dexamethasone plasma 
concentration–time course was described as: 
The initial slope (αp) of the plasma dexamethasone con-
centration–time course was described as: 
The terminal half-life (t1/2β) of the plasma dexametha-
sone concentration–time course was described as: 
(9)θparameter_i = θtv_parameter · eη
(10)η ≈ N
[
0,ω2
]
(11)shrinkage = 1− SD
(
EBEη
)
ω
(12)Cl = θtvCl · [1+ θ1doselevel]
(13)
βp = 0.5 ·
[
Cld
Vc
+
Cld
Vt
+
Cl
Vc
−
[(
Cld
Vc
+
Cld
Vt
+
Cl
Vc
)2
−4
Cld
Vt
·
Cl
Vc
]0.5]
(14)αp =
Cld
Vt
·
Cl
Vc
β
The initial half-life (t1/2α) of the plasma dexamethasone 
concentration–time courses was described as: 
LPS‑challenge model and lameness response analyses
The LPS synovial concentration was not known and 
the time course of the challenge function (SLPS) was 
described as:
where ALPS1, ALPS2, kLPS1 and kLPS2 represent the maximal 
input rates and the rate constant controlling the time 
development of the challenge function. The gamma (γ1, 
γ2) parameters are exponents amplifying the response to 
the challenge. The rate of change 
(
dR
dt
)
 of lameness 
response measured by means of Lameness  locator® was 
then described as follows:
where kout and R represent the fractional turnover rate of 
response and the lameness response.
Dexamethasone was assumed to inhibit lameness 
response to the LPS challenge. A sequential approach 
was adopted to estimate the PD parameters. The post hoc 
estimates of individual PK parameters were fixed to their 
post hoc estimate to ‘drive’ the inhibitory function [25]. 
The inhibitory function (I(Cs)) was described as:
where Imax and IC50 are the maximum drug-induced 
inhibition of lameness response and the dexamethasone 
synovial fluid concentration at 50% reduction in the 
lameness response, respectively.
The drug mechanism function was then incorporated 
in Eq. (16) to give Eq. (18): 
Phoenix NLME version 8.0 (Certara, St. Louis, MO, 
USA) was used in regression of data. A multiplica-
tive (proportional) error (weighting) model was used 
(15)t1/2β =
ln2
β
(16)t1/2α =
ln2
∝
(17)
SLPS =
[
ALPS1 · kLPS1 · t · e
−kLPS1·t
]γ 1
+
[
ALPS2 · kLPS2 · t · e
−kLPS2·t
]γ 2
(18)dR
dt
= SLPS − kout · R
(19)I(Cs) = 1−
Imax · Csyn
IC50 + Csyn
(20)dR
dt
= SLPS · I(Cs)− kout · R
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for weighting dexamethasone-time data and lameness 
response-time data.
Statistics
Independently of the PK/PD-modelling approach the 
data was subjected to conventional statistical hypothesis 
testing by means of a linear mixed-effects model. Time 
and dose were used as categorical fixed effects and horse 
as random effect. Data was compared between doses for 
every time-point. An ad hoc analysis (Dunnett’s test) was 
performed in order to compare data after LPS adminis-
tration with the pre-administration data. The repeated 
measures structure of the data was accounted for by 
including an autoregressive correlation structure on the 
error term within each individual. Statistical significance 
was considered when P < 0.05. All statistical analyses were 
performed using the statistical software R version 3.4.4 
(The R Foundation for Statistical Computing, Vienna, 
Austria).
Results
Disposition of dexamethasone
In the horses receiving the four lower doses, dexametha-
sone was quantifiable (LLOQ 0.38  ng/mL) in synovial 
fluid samples collected 2, 4 and 8 h after injection. In the 
horses receiving the two higher doses, dexamethasone 
was quantifiable up to 30 h (six samples) after injection 
(Fig. 2).
For horse F that received 0.01  mg dexamethasone IA 
no dexamethasone plasma concentrations were quan-
tifiable (LLOQ 0.025  ng/mL). For horse C that received 
0.03  mg, dexamethasone was only quantifiable in the 
samples collected 5 and 20 min after DSP injection (both 
0.03  ng/mL). In the horses receiving the four higher 
doses (Table  1) dexamethasone was quantifiable up to 
24 h (5–7 plasma samples) and maximum concentration 
was observed within 40 min (Fig. 2).
A three-compartment model (including one com-
partment for synovial fluid) was fitted to experimental 
dexamethasone synovial fluid data and dexamethasone 
plasma data from all horses in this study and from lit-
erature plasma raw data collected from [21]. The model 
estimated and derived pharmacokinetic parameters from 
the horses in this study are shown in Table 2. Experimen-
tal dexamethasone data were evenly distributed around 
the line of unity for both the structural and the random 
component of the three compartment model (Fig. 3). The 
conditional weighted residuals (CWRES) over time were 
concentrated between y = − 2 and y = + 2 for dexametha-
sone plasma and synovial fluid concentrations (Fig.  4). 
The typical values for disposition in synovial fluid and 
plasma are given in Table  2. The typical value for total 
plasma clearance of dexamethasone was 246  mL/kg/h. 
For literature data from [21], dexamethasone was admin-
istered in three doses. Hence, dose was used as a covari-
ate and clearance was 426  mL/kg/h and 428  mL/kg/h 
after administration of the intermediate and the high 
dose. The t1/2α and t1/2β in plasma was 0.6  h and 4.3  h. 
The fraction of the administered dose that was eliminated 
directly from the joint without gaining access to plasma 
for the first 48 h after administration was 0.5–2.1%.  
There were no differences in clinical endpoint baseline 
between the two treatment protocols. The LPS + saline 
treatment increased objective lameness score using 
objective  (HDmin) lameness data compared to baseline at 
4  h (P < 0.001) and 6  h (P < 0.001) after LPS-administra-
tion. The LPS + DSP treatment did not increase lameness 
score compared to baseline using  HDmin data. After treat-
ment with LPS + DSP the horses were less lame at 4 h (P 
0.001), 6  h (P= 0.004) and 10  h (P = 0.04) compared to 
treatment with LPS + saline (Fig.  5a). The LPS + saline 
treatment increased subjective lameness score compared 
to baseline at 4 h (P < 0.001) and 6 h (P < 0.001) after LPS-
administration. The LPS + DSP treatment increased sub-
jective lameness score at 4  h (P = 0.008) compared to 
baseline. After treatment with LPS + DSP horses were 
less lame at 6 h (P = 0.008), compared to treatment with 
LPS + saline (Fig. 5b).
There was no difference in JC and ST between the two 
treatments. For RT no difference between the two treat-
ments was observed from 0 to 72  h. At 76  h RT was 
higher in the LPS + saline group (P = 0.03). No signs of 
septic arthritis were observed during or in the following 
days after LPS injection and sample collection.
Subjective and objective  (HDmin) lameness scores are 
shown in Fig. 5. The LPS-challenge + intra articular saline 
induced an increase in  HDmin (indicating impact lame-
ness in the induced limb) in all horses compared to base-
line. Median (range)  HDmin was 96  mm (12–196). The 
maximum  HDmin was observed within 8 h in all horses. 
The  HDmin score then returned to baseline within 24  h 
after LPS-challenge in five horses and within 32 h in one 
horse. A pharmacodynamic model was fitted to experi-
mental lameness response data from all horses. Experi-
mental  HDmin data were evenly distributed around the 
line of unity for both the structural and the random com-
ponent of the pharmacodynamics model (Fig. 6). CWRES 
over time were concentrated between y = − 2 and y = + 2 
for lameness data (Fig.  7). The model estimated typical 
values are shown in Table 3
Discussion
This study investigated and described dexamethasone 
disposition in synovial fluid and plasma after IA admin-
istration of DSP in the inflamed equine joint. Simulta-
neously it reports the relation between synovial fluid 
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and plasma concentration and CE response to IA dexa-
methasone treatment. The present data were analysed 
with a NLME model (also known as population model-
ling) consistent with the U.S Food and Drug Admin-
istration guidelines [23]. The population PK approach 
allows the analysis of data from a variety of unbalanced 
designs as well as from studies that are normally excluded 
because they do not lend themselves to the usual forms 
of pharmacokinetic analysis, such as concentration 
data obtained from paediatric and elderly patients, or 
data obtained during the evaluation of the relationships 
between dose or concentration and efficacy or safety [26]. 
For our data sets, a classical two-stages analysis led to the 
biased estimate of some parameters as the IC50 due to 
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outlying individual estimate whereas the NLME-analyses 
allowed the estimate of robust typical (here synonym of 
mean) values of these parameters even if the between 
subject variability was not properly estimated for some 
parameters from our limited number of horses. This 
approach is also recommended in toxicokinetic trials for 
which a limited number of subject are often investigated 
using different unbalanced and sparsely sampling design 
[27, 28].
The pharmacokinetic model fitted to experimental syn-
ovial fluid dexamethasone data satisfactory mimicked the 
data and no major bias or model misspecifications were 
suspected (Figs. 3 and 4). Quantitative information about 
synovial fluid and plasma disposition of dexamethasone 
was provided (Table  2). To our knowledge, the dexa-
methasone concentration–time course in synovial fluid 
has not previously been reported. In plasma, the total 
clearance, the central and peripheral volume of distribu-
tion and the initial and terminal half-lives were consist-
ent with the literature [8, 21, 29, 30]. Dexamethasone 
was removed from the joint when synovial fluid was col-
lected and possibly by enzymatic breakdown in the joint. 
The cumulative amount directly removed from the joint 
was 0.5–2.1% of the administered dose. This a suggest a 
systemic bioavailability around 98–99.5% for dexameth-
asone after IA injection in the inflamed joint, which is 
consistent with the bioavailability of dexamethasone after 
IA-administration in the healthy carpal joint [8]. The very 
low value for kel indicate that the half-life of dexametha-
sone in inflamed synovial fluid is similar to the half-life in 
plasma (the t1/2α and t1/2β in plasma was 0.6 h and 4.3 h, 
respectively). This is consistent with our preliminary cal-
culations of dexamethasone half-life in inflamed synovial 
fluid (terminal half-life: 0.9–3.3  h) published elsewhere 
[31]
In both experimental and clinical studies joint swell-
ing and lameness has been used as biomarkers after 
intra-articular glucocorticoid therapy in horses [3, 4, 6, 
7]. LPS-challenge has been used previously to induce 
inflammation in the equine joint [32–36]. Doses up to 
2.5  ng LPS per joint caused a mild to moderate local 
joint inflammation that resolved within 36  h, whereas 
doses above 125 ng also caused signs of systemic inflam-
mation. This study demonstrates between animal lame-
ness  (HDmin) variation after LPS challenge followed by 
saline injection (Fig.  5). This variation is not showed in 
the amplitude parameter, which is a consequence of the 
additional γ1-parameter and γ2-parameter. However, the 
γ-parameters were necessary to capture the peak and 
duration in lameness response. This was important to 
accurately fit the model to experimental data and esti-
mation of model-parameters. Despite following strict 
procedures when injections were performed, incom-
plete intra-articular injection might have contributed to 
variation in response to the LPS-challenge and the dexa-
methasone treatment between the horses. Aspiration of 
synovial fluid followed by injection performed without 
resistance was used as confirmation of the needle place-
ment within the joint cavity.
Lameness scores were lower after treatment with 
LPS + DSP than with LPS + saline. Five of the horses 
(Table 1) were treated with doses lower than the labelled 
dose 2–10  mg/joint [37]. In this study, the objective 
lameness assessment was a more sensitive method to 
evaluate lameness compared with the visual assessment. 
The inertial sensor based system has been validated for 
lameness detection and shown repeatability when used 
in a straight line as in this study and is comparable with 
optical based motion capture [20, 38, 39]. It has also 
been proposed that high intra- and interrater variability 
may bias and limit the usefulness of subjective lameness 
assessment [40–43]. The use of non-linear mixed effects 
model allowed fitting of a pharmacodynamic model to 
the sparse experimental objective lameness data and the 
Table 2 Model typical values (tv) and the individual pharmacokinetic parameter estimates for the horses A–F
Where tv is the typical value for the population, dose is the amount dexamethasone administered into the joint, Vsyn, Vc and Vt are the volume of distribution in the 
synovial compartment (typical value was fixed to 0.2 mL/kg), the central compartment and the peripheral compartment, respectively. Cl is the plasma clearance and 
Cld is the inter-compartmental distribution parameter. kap, kpa and kel are the rate constants from the joint to the plasma, the plasma to the joint and direct elimination 
from the joint, respectively. Note that shrinkage was high (> 0.3) for kap, kpa kel, Vsyn and Cl due to a poor estimate of the random component of the model for these 
parameters and corresponding post hoc values were shrinked toward their population values
Horse Dose (mg) Vsyn (mL/kg) kap (1/h) kpa (1/h) kel (1/h) Vc (mL/kg) Vt (mL/kg) Cl (mL/kg/h) Cld (mL/kg/h)
tv na 0.2 0.6 0.15 0.010 338 1123 246 495
F 0.01 0.49 0.61 0.15 0.010 279 1135 247 491
C 0.03 0.27 0.61 0.14 0.011 148 1114 253 690
B 0.1 0.26 0.65 0.14 0.013 126 1018 266 778
A 0.3 0.18 0.74 0.15 0.009 85 997 417 598
D 1 0.20 1.06 0.15 0.010 308 1133 446 637
E 3 0.03 1.91 0.15 0.010 230 1263 470 763
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quantitative information of the pharmacodynamics was 
estimated (Figs.  6 and 7, Table 3). Both the dexametha-
sone synovial fluid potency (IC50) and efficacy (Imax) 
values were derived as well as model parameters for the 
LPS-challenge. The IC50 and Imax values are similar to 
what has been reported potency and efficacy values for 
glucose response in horses [44]. For all parameters for 
which the random component of the model was esti-
mable, the BSV was relatively small (Tables  2 and 3). 
However, the shrinkage was high for the two pivotal 
pharmacodynamic parameters (IC50 and Imax) indicat-
ing that the between subject variation for these two 
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parameters was not estimable from our data set and it 
was impossible to estimate accurate individual IC50 and 
Imax (post hoc) values [24]. However we robustly esti-
mated a typical value that should deserve attention.
Decreasing the dose may offer both benefits and dis-
advantages. Lower doses have lower risk for obvious 
systemic effects but also shorter duration of the local 
response in the joint. The use of lower doses may poten-
tially increase the number of injections to uphold drug 
exposure over time. There are case reports describ-
ing septic arthritis following intra articular injections 
in the horse [45]. In the present study, totally 156 joint 
punctures were performed. There were no signs of sep-
tic arthritis during the study or in the following days. 
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The result suggests that the risk for infection is low when 
aseptic injection techniques are used. This is also sup-
ported by a recent suggestion that infection is uncommon 
following joint injections [46]. However, septic arthritis is 
a severe condition and the risk should not be neglected. 
Higher doses would reduce the number of injections to 
maintain therapeutic concentrations in synovial fluid and 
consequently the risk for septic arthritis. However, there 
is some conflicting evidence for the risk of detrimen-
tal effects on articular cartilage at high glucocorticoid 
doses administered IA [47–49]. High doses also increase 
systemic exposure and might produce adverse systemic 
effects e.g. hyperglycaemia, hyperinsulinemia and poten-
tially laminitis [50–52]. Further studies are warranted 
to evaluate if the benefit from lower doses outweigh the 
risks with repeated injections.
The variables JC (joint circumference) and ST (local 
skin temperature) were not statistically different 
between treatments. Both JC and ST have been used in 
response studies of anti-inflammatory drugs and there is 
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conflicting evidence for decrease in those variables. Mor-
phine has anti-inflammatory properties and decreased 
ST and JC in equine synovitis [33]. Despite that non-
steroidal drugs might decrease ST, JC in horses or paw-
swelling in dogs may not decrease which suggest that JC 
may not be a suitable biomarker for the anti-inflamma-
tory responses in acute synovitis [53–56]. A likely expla-
nation for the non-significant results in ST in this study 
is the low dexamethasone exposure following the low-
est doses used combined with the relatively low power 
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caused by study with only six horses. Consistent with 
this study significant lameness reduction and no decrease 
in JC after IA glucocorticoid administration has been 
reported elsewhere [4].
Conclusion
The synovial disposition and the response to dexametha-
sone were characterised in an equine model of synovitis 
after a single IA administration of DSP. The inertial sen-
sor based lameness scoring system was the most sensi-
tive of the methods used to evaluate the response to 
dexamethasone in this study. The presented quantitative 
information can be used as input for both future research 
and programs intended to upheld integrity and horse 
welfare in horseracing and equestrian sports. Dexa-
methasone synovial fluid half-life was considered similar 
to that in plasma. A tentative potency and efficacy value 
for lameness reduction was proposed. Lameness was 
suppressed after treatment with dexamethasone despite 
doses lower than labelled doses (2–10 mg). Low doses of 
DSP combined with short half-life of dexamethasone in 
synovial fluid following IA administration will result in 
short duration of response, which must be considered in 
clinical treatment.
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